Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Braveheart Bio, Inc.BRVE · Entity 4564 | Director | August 05, 2026 | August 07, 2026 |
| Forbion European Acquisition Corp.FRBNU · Entity 108709 | Chief Executive Officer | December 09, 2021 | December 09, 2021 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Director | June 16, 2025 | June 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Braveheart Bio, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-08-04 | Direct | 30,000 |
Reported balance
After 2026-08-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-05 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Forbion European Acquisition Corp.
Report date December 09, 2021 · Filed December 09, 2021
This filing explicitly reported no securities owned.
enGene Therapeutics Inc.
Report date June 16, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.31 · Expires 2035-06-16 | Direct | 22,500 |
Reported balance
After 2025-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-16 · Grant · Acquired 22,500 · Balance 22,500 F1: This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 20:30 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000797 · wk-form4_1786134641.xml · derivative · entry 1 Bos Jasper · CIK 0001897789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-08-04 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| June 16, 2025 Filed Jun 16, 2025 22:36 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0000929638-25-002247 · form4.xml · derivative · entry 1 Bos Jasper · CIK 0001897789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2035-06-16 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 20:05 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0000929638-24-002213 · form4.xml · derivative · entry 1 Bos Jasper · CIK 0001897789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2034-06-15 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.